Global Serological Pipettes Market, by Product (1-2 ml, 5 ml, 10 ml, 25 ml, and Other (50 ml etc.)), by Material (Glass Pipettes, Plastic Pipettes, Polystyrene Pipettes, and Others), by Application (Tissue Culture, Bacterial Culture, Testing Lab, and Others), by End User (Hospitals, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America), was valued at US$ 188.2 Million in 2021 and is projected to exhibit a CAGR of 4.7% during the forecast period (2021-2028).
The increasing investment in research and development (R&D) activities is expected to significantly contribute to the global pipettes and accessories market growth. Pharmaceutical companies are focusing on increasing R&D activities along with outsourcing research activities to academic research institutes. For instance, in September 2016, Syngene International, a Biocon CRO, established Syngene Amgen Research and Development Center (SARC), a drug discovery research laboratory and multi-disciplinary development center, for Amgen in Bengaluru, India.
Global Serological Pipettes Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 pandemic has affected various industries globally. The players operating in the global serological pipettes market are facing major challenges on various fronts due to the COVID-19 pandemic. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally, as of November 16, 2021, are about 253,640,693 confirmed cases with 5,104,899 deaths.
The COVID-19 pandemic caused major disruptions to clinical trial executions in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced disturbances, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, contract research organizations, and other organizations that support drug development shifted to remote working environments.